Inhibitory effect of peptide Epitalon on colon carcinogenesis induced by 1,2-dimethylhydrazine in rats

The full body text was not directly accessible during this extraction pass (paywalled on ScienceDirect; the Khavinson-info PDF mirror was returning 503 at extraction time). The headline numerical results — 80 rats, 4 arms of 20, DMH 21 mg/kg weekly for 5 weeks, Epitalon 1 microgram five days a week, 6-month follow-up, 90-100% colon carcinoma incidence, total colon tumors per rat of 4.1 / 2.7 / 3.7 / 2.9 across groups 1-4, significant difference for groups 2 and 4 vs group 1 — are verified verbatim across PubMed, ScienceDirect, and three independent secondary indexes. Per-arm tumor-incidence percentages, exact p-values for each anatomic site, tumor size measurements, and any survival or mortality data before sacrifice are in the body and not asserted in this entry.

Seven methodological caveats apply at the abstract level:

1. Single-lab, inventor-group institutional COI. All four authors are affiliated with the N.N. Petrov Research Institute of Oncology and the St. Petersburg Institute of Bioregulation and Gerontology; Khavinson is the inventor and patent-holder for Epitalon. No independent replication of this specific finding is visible in the searchable literature; the 2003 Kossoy et al. follow-up shares co-authors and re-analyzes the same animals, so it is best read as a companion analysis rather than independent replication. The broader "decades-of-safety-and-efficacy record" narrative around the Khavinson short-peptide program rests on a closed-loop publication network of this kind — see the Russian peptides safety-record myth response for the longer treatment of how the corpus's single-lab provenance should be weighted.

2. Single sex, single strain. Male outbred LIO rats only. LIO is a Russian outbred line that is not widely used outside of St. Petersburg labs, which limits cross-comparison with the more common DMH-model strains (Sprague-Dawley, Wistar, F344).

3. Single dose of Epitalon. 1 microgram per animal per injection, no dose-response. Notably this is 10x the dose used in the CBA mice longevity paper (0.1 microgram per animal) and on a much heavier schedule (five days a week for 6 months vs five days a month for life) — so the two papers are not testing the same pharmacology, and the cancer-prevention effect cannot be assumed to operate at the longevity-paper dose.

4. Small sample sizes per arm. Twenty rats per arm is adequate for detecting large effect sizes against a 90-100% incidence baseline but underpowered for detecting modest effects on tumor multiplicity, and underpowered for subgroup analysis (ascending vs descending colon vs jejunum vs ileum).

5. DMH model translatability. DMH-induced rat colon carcinogenesis is the standard mid-20th-century chemical-induction colon-cancer model. It produces a high penetrance of adenocarcinoma via a known DNA-adduct mechanism (DMH → methyldiazonium → O6-methylguanine adducts) that is unlike the APC-pathway-driven human sporadic colorectal cancer in genesis. Effects in the DMH model do not reliably translate to human colorectal-cancer chemoprevention — many compounds active in DMH-rat have failed in human trials. This is a general caveat of the model, not specific to Epitalon.

6. Short-vs-long-term distinction. Follow-up was 6 months from start of DMH (the Kossoy 2003 companion paper specifies this). Late-emerging tumors, metastasis, and survival differences past 6 months are not addressed. The paper measures tumor count at a fixed timepoint, not lifetime tumor burden or cancer-specific mortality.

7. Mechanism question. The paper's mechanism story is interpretive — the abstract does not anchor the tumor reduction to a specific molecular pathway, and the 2003 companion's mitotic-index-down / apoptosis-up finding describes the phenotype but does not nail down which signaling axis is implicated. Whether the effect is immune-mediated, melatonin-axis-mediated, directly anti-proliferative, or DNA-binding (the later Khavinson-Linkova short-peptide-as-transcriptional-modulator hypothesis published as Khavinson 2015 KEDW epigenetic mechanism) is not settled in this paper. The telomerase-induction line of the program (Khavinson 2003) is the marketing-facing mechanism but is in tension with the chemoprevention finding documented here — telomerase reactivation is mechanistically tumor-permissive in cell-line models, and the literature has not reconciled how a peptide can both lift telomerase activity and suppress chemically-induced tumor formation. The biohacker shortcut from "telomerase activator" to "anti-aging peptide" is examined in the telomere anti-aging overstatement critic page.

The cancer-prevention claim, taken on its abstract-level evidence: real within this experimental design, statistically significant for the load-bearing endpoint (total colon tumors per rat), single-lab and not independently replicated.